562 related articles for article (PubMed ID: 15158434)
1. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
5. Active and inactive conformations of the epidermal growth factor receptor.
Ferguson KM
Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003
[TBL] [Abstract][Full Text] [Related]
6. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
7. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
[TBL] [Abstract][Full Text] [Related]
9. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
10. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
Fuller SJ; Sivarajah K; Sugden PH
J Mol Cell Cardiol; 2008 May; 44(5):831-54. PubMed ID: 18430438
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
[TBL] [Abstract][Full Text] [Related]
12. EGFR family: structure physiology signalling and therapeutic targets.
Burgess AW
Growth Factors; 2008 Oct; 26(5):263-74. PubMed ID: 18800267
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
14. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
16. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.
Tao RH; Maruyama IN
J Cell Sci; 2008 Oct; 121(Pt 19):3207-17. PubMed ID: 18782861
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) signaling in cancer.
Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
[TBL] [Abstract][Full Text] [Related]
18. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
19. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]